Evidence map›Paper›PMID 26851519›Full record

ArticleJournal of immunological methods2016

pMINERVA: A donor-acceptor system for the in vivo recombineering of scFv into IgG molecules.

M Batonick, M M Kiss, E P Fuller, C M Magadan, E G Holland, Q Zhao, D Wang, B K Kay, M P Weiner

Open access · greenAbstract read
In one paragraph

Article in Journal of immunological methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

M BatonickAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States. Electronic address: mbatonick@axiomxinc.com.
M M KissAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
E P FullerAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
C M MagadanAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
E G HollandAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Q ZhaoAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
D WangAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
B K KayUniversity of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607, United States.
M P WeinerAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
AxioMx (United States) · USUniversity of Illinois Chicago · US

Funding

Vector and strain system for the in vivo conversion of antibody fragments into IgG moleculesR43GM112204 · NIGMS · AXIOMX, INC. · PI WEINER, MICHAEL P · 2015 to 2015
$216k
NIGMS NIH HHS 1R43GM1122204-01A1NIGMS NIH HHS R43 GM112204
6 · The paper itself

Abstract

Phage display is the most widely used method for selecting binding molecules from recombinant antibody libraries. However, validation of the phage antibodies often requires early production of the cognate full-length immunoglobulin G (IgG). The conversion of phage library outputs to a full immunoglobulin via standard subcloning is time-consuming and limits the number of clones that can be evaluated. We have developed a novel system to convert scFvs from a phage display vector directly into IgGs without any in vitro subcloning steps. This new vector system, named pMINERVA, makes clever use of site-specific bacteriophage integrases that are expressed in Escherichia coli and intron splicing that occurs within mammalian cells. Using this system, a phage display vector contains both bacterial and mammalian regulatory regions that support antibody expression in E. coli and mammalian cells. A single-chain variable fragment (scFv) antibody is expressed on the surface of bacteriophage M13 as a genetic fusion to the gpIII coat protein. The scFv is converted to an IgG that can be expressed in mammalian cells by transducing a second E. coli strain. In that strain, the phiC31 recombinase fuses the heavy chain constant domain from an acceptor plasmid to the heavy chain variable domain and introduces controlling elements upstream of the light chain variable domain. Splicing in mammalian cells removes a synthetic intron containing the M13 gpIII gene to produce the fusion of the light chain variable domain to the constant domain. We show that phage displaying a scFv and recombinant IgGs generated using this system are expressed at wild-type levels and retain normal function. Use of the pMINERVA completely eliminates the labor-intensive subcloning and DNA sequence confirmation steps currently needed to convert a scFv into a functional IgG Ab.

Indexed as

Cell Surface Display TechniquesBacteriophagesHumansImmunoglobulin GIntegrasesSingle-Chain AntibodiesImmunoglobulin GIntegrasesSingle-Chain AntibodiesIgGRecombineeringScFvSplicing

Identifiers

PMID26851519
PMCPMC4792691
OpenAlexW2258857088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.